207 related articles for article (PubMed ID: 19889173)
21. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study.
Lamfon H; Porter SR; McCullough M; Pratten J
J Antimicrob Chemother; 2004 Feb; 53(2):383-5. PubMed ID: 14729749
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility of Candida albicans to photodynamic therapy in a murine model of oral candidosis.
Mima EG; Pavarina AC; Dovigo LN; Vergani CE; Costa CA; Kurachi C; Bagnato VS
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):392-401. PubMed ID: 20060338
[TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of anti-Candida potential of geranium oil constituents against clinical isolates of Candida albicans differentially sensitive to fluconazole: inhibition of growth, dimorphism and sensitization.
Zore GB; Thakre AD; Rathod V; Karuppayil SM
Mycoses; 2011 Jul; 54(4):e99-109. PubMed ID: 20337938
[TBL] [Abstract][Full Text] [Related]
26. [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004].
Eloy O; Blanc V; Pina P; Gaudart A; Bressolle ML; Plainvert C; Decousser JW; Pangon B; Allouch PY;
Pathol Biol (Paris); 2006; 54(8-9):523-30. PubMed ID: 17029814
[TBL] [Abstract][Full Text] [Related]
27. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
Mondello F; De Bernardis F; Girolamo A; Salvatore G; Cassone A
J Antimicrob Chemother; 2003 May; 51(5):1223-9. PubMed ID: 12668571
[TBL] [Abstract][Full Text] [Related]
29. [Antifungal agents can change the balance between resistant and susceptible Candida species].
Petrini B; Chryssanthou E
Lakartidningen; 2002 May; 99(20):2293-4. PubMed ID: 12082947
[TBL] [Abstract][Full Text] [Related]
30. Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan.
Yang YL; Cheng HH; Ho YA; Hsiao CF; Lo HJ
J Microbiol Immunol Infect; 2003 Sep; 36(3):187-91. PubMed ID: 14582563
[TBL] [Abstract][Full Text] [Related]
31. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
32. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.
Posteraro B; Martucci R; La Sorda M; Fiori B; Sanglard D; De Carolis E; Florio AR; Fadda G; Sanguinetti M
J Clin Microbiol; 2009 Jun; 47(6):1927-30. PubMed ID: 19403774
[TBL] [Abstract][Full Text] [Related]
33. Potential of plant oils as inhibitors of Candida albicans growth.
Devkatte AN; Zore GB; Karuppayil SM
FEMS Yeast Res; 2005 Jun; 5(9):867-73. PubMed ID: 15925315
[TBL] [Abstract][Full Text] [Related]
34. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic
Kane A; Dinh H; Campbell L; Cain AK; Hibbs D; Carter D
Microbiol Spectr; 2024 Jun; 12(6):e0012124. PubMed ID: 38695556
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of secretory aspartyl protease production in biofilms of Candida albicans exposed to sub-inhibitory concentrations of fluconazole.
Mores AU; Souza RD; Cavalca L; de Paula e Carvalho A; Gursky LC; Rosa RT; Samaranayake LP; Rosa EA
Mycoses; 2011 May; 54(3):195-201. PubMed ID: 19878458
[TBL] [Abstract][Full Text] [Related]
37. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures.
Wei GX; Xu X; Wu CD
Arch Oral Biol; 2011 Jun; 56(6):565-72. PubMed ID: 21272859
[TBL] [Abstract][Full Text] [Related]
38. Reduced biocide susceptibility in Candida albicans biofilms.
Nett JE; Guite KM; Ringeisen A; Holoyda KA; Andes DR
Antimicrob Agents Chemother; 2008 Sep; 52(9):3411-3. PubMed ID: 18573927
[TBL] [Abstract][Full Text] [Related]
39. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.
Kamai Y; Kakuta M; Shibayama T; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Jan; 49(1):52-6. PubMed ID: 15616275
[TBL] [Abstract][Full Text] [Related]
40. Role for cell density in antifungal drug resistance in Candida albicans biofilms.
Perumal P; Mekala S; Chaffin WL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2454-63. PubMed ID: 17502416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
